Does the media refer more to INDV or JAZZ?

In the previous week, Jazz Pharmaceuticals had 8 more articles in the media than Indivior. MarketBeat recorded 12 mentions for Jazz Pharmaceuticals and 4 mentions for Indivior. Indivior's average media sentiment score of 1.04 beat Jazz Pharmaceuticals' score of 0.44 indicating that Indivior is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indivior 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jazz Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to INDV or NBIX?

In the previous week, Neurocrine Biosciences had 10 more articles in the media than Indivior. MarketBeat recorded 14 mentions for Neurocrine Biosciences and 4 mentions for Indivior. Indivior's average media sentiment score of 1.04 beat Neurocrine Biosciences' score of 0.87 indicating that Indivior is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indivior 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neurocrine Biosciences 7 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to INDV or CORT?

In the previous week, Corcept Therapeutics had 24 more articles in the media than Indivior. MarketBeat recorded 28 mentions for Corcept Therapeutics and 4 mentions for Indivior. Indivior's average media sentiment score of 1.04 beat Corcept Therapeutics' score of 0.73 indicating that Indivior is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indivior 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corcept Therapeutics 9 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor ELAN or INDV?

In the previous week, Elanco Animal Health had 7 more articles in the media than Indivior. MarketBeat recorded 11 mentions for Elanco Animal Health and 4 mentions for Indivior. Indivior's average media sentiment score of 1.04 beat Elanco Animal Health's score of 0.66 indicating that Indivior is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Indivior 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to INDV or AXSM?

In the previous week, Axsome Therapeutics had 9 more articles in the media than Indivior. MarketBeat recorded 13 mentions for Axsome Therapeutics and 4 mentions for Indivior. Indivior's average media sentiment score of 1.04 beat Axsome Therapeutics' score of 0.65 indicating that Indivior is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indivior 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 6 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Indivior (INDV) Competitors

$34.88 -0.81 (-2.27%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$34.88 -0.01 (-0.01%)

As of 09/18/2026 07:43 PM Eastern

Compare

INDV vs. JAZZ, NBIX, CORT, ELAN, and AXSM

Should you buy Indivior stock or one of its competitors? Indivior's main competitors and comparable companies include Jazz Pharmaceuticals (JAZZ), Neurocrine Biosciences (NBIX), Corcept Therapeutics (CORT), Elanco Animal Health (ELAN), and Axsome Therapeutics (AXSM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Indivior compare to Jazz Pharmaceuticals?

Indivior (NASDAQ:INDV) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

60.3% of Indivior shares are held by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 0.7% of Indivior shares are held by insiders. Comparatively, 4.1% of Jazz Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Indivior has a net margin of 26.65% compared to Jazz Pharmaceuticals' net margin of 20.45%. Jazz Pharmaceuticals' return on equity of 33.97% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	26.65%	-283.11%	36.85%
Jazz Pharmaceuticals	20.45%	33.97%	13.02%

Indivior currently has a consensus target price of $45.17, suggesting a potential upside of 29.49%. Jazz Pharmaceuticals has a consensus target price of $286.72, suggesting a potential upside of 19.10%. Given Indivior's higher probable upside, equities analysts clearly believe Indivior is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	3.00

Indivior has a beta of 0.82, indicating that its share price is 18% less volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.36, indicating that its share price is 64% less volatile than the broader market.

Indivior has higher earnings, but lower revenue than Jazz Pharmaceuticals. Indivior is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.24B	3.32	$210M	$2.79	12.50
Jazz Pharmaceuticals	$4.27B	3.66	-$356.15M	$14.50	16.60

In the previous week, Jazz Pharmaceuticals had 8 more articles in the media than Indivior. MarketBeat recorded 12 mentions for Jazz Pharmaceuticals and 4 mentions for Indivior. Indivior's average media sentiment score of 1.04 beat Jazz Pharmaceuticals' score of 0.44 indicating that Indivior is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indivior	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Jazz Pharmaceuticals beats Indivior on 11 of the 17 factors compared between the two stocks.

How does Indivior compare to Neurocrine Biosciences?

Indivior (NASDAQ:INDV) and Neurocrine Biosciences (NASDAQ:NBIX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

60.3% of Indivior shares are owned by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are owned by institutional investors. 0.7% of Indivior shares are owned by company insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Indivior has a beta of 0.82, meaning that its stock price is 18% less volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market.

Indivior has a net margin of 26.65% compared to Neurocrine Biosciences' net margin of 20.91%. Neurocrine Biosciences' return on equity of 22.43% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	26.65%	-283.11%	36.85%
Neurocrine Biosciences	20.91%	22.43%	15.64%

Indivior presently has a consensus target price of $45.17, suggesting a potential upside of 29.49%. Neurocrine Biosciences has a consensus target price of $201.09, suggesting a potential upside of 37.52%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Neurocrine Biosciences is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Neurocrine Biosciences had 10 more articles in the media than Indivior. MarketBeat recorded 14 mentions for Neurocrine Biosciences and 4 mentions for Indivior. Indivior's average media sentiment score of 1.04 beat Neurocrine Biosciences' score of 0.87 indicating that Indivior is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indivior	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurocrine Biosciences	7 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neurocrine Biosciences has higher revenue and earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.24B	3.32	$210M	$2.79	12.50
Neurocrine Biosciences	$2.86B	5.20	$478.60M	$6.82	21.44

Summary

Neurocrine Biosciences beats Indivior on 13 of the 17 factors compared between the two stocks.

How does Indivior compare to Corcept Therapeutics?

Indivior (NASDAQ:INDV) and Corcept Therapeutics (NASDAQ:CORT) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

Indivior has a net margin of 26.65% compared to Corcept Therapeutics' net margin of 6.52%. Corcept Therapeutics' return on equity of 8.26% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	26.65%	-283.11%	36.85%
Corcept Therapeutics	6.52%	8.26%	6.45%

In the previous week, Corcept Therapeutics had 24 more articles in the media than Indivior. MarketBeat recorded 28 mentions for Corcept Therapeutics and 4 mentions for Indivior. Indivior's average media sentiment score of 1.04 beat Corcept Therapeutics' score of 0.73 indicating that Indivior is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indivior	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corcept Therapeutics	9 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Indivior has higher revenue and earnings than Corcept Therapeutics. Indivior is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.24B	3.32	$210M	$2.79	12.50
Corcept Therapeutics	$830.81M	14.35	$99.65M	$0.42	262.60

60.3% of Indivior shares are held by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are held by institutional investors. 0.7% of Indivior shares are held by company insiders. Comparatively, 20.7% of Corcept Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Indivior has a beta of 0.82, indicating that its share price is 18% less volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market.

Indivior presently has a consensus price target of $45.17, suggesting a potential upside of 29.49%. Corcept Therapeutics has a consensus price target of $138.17, suggesting a potential upside of 25.28%. Given Indivior's stronger consensus rating and higher possible upside, analysts clearly believe Indivior is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Corcept Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Indivior beats Corcept Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Indivior compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Indivior (NASDAQ:INDV) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

Indivior has a net margin of 26.65% compared to Elanco Animal Health's net margin of -3.96%. Elanco Animal Health's return on equity of 8.13% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-3.96%	8.13%	3.99%
Indivior	26.65%	-283.11%	36.85%

Elanco Animal Health has a beta of 1.68, meaning that its stock price is 68% more volatile than the broader market. Comparatively, Indivior has a beta of 0.82, meaning that its stock price is 18% less volatile than the broader market.

97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 1.1% of Elanco Animal Health shares are owned by company insiders. Comparatively, 0.7% of Indivior shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Elanco Animal Health currently has a consensus price target of $29.09, indicating a potential upside of 29.92%. Indivior has a consensus price target of $45.17, indicating a potential upside of 29.49%. Given Elanco Animal Health's higher probable upside, analysts plainly believe Elanco Animal Health is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Indivior	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Indivior has lower revenue, but higher earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.37	-$232M	-$0.41	N/A
Indivior	$1.24B	3.32	$210M	$2.79	12.50

In the previous week, Elanco Animal Health had 7 more articles in the media than Indivior. MarketBeat recorded 11 mentions for Elanco Animal Health and 4 mentions for Indivior. Indivior's average media sentiment score of 1.04 beat Elanco Animal Health's score of 0.66 indicating that Indivior is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Indivior	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Elanco Animal Health beats Indivior on 9 of the 17 factors compared between the two stocks.

How does Indivior compare to Axsome Therapeutics?

Indivior (NASDAQ:INDV) and Axsome Therapeutics (NASDAQ:AXSM) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

Indivior currently has a consensus price target of $45.17, suggesting a potential upside of 29.49%. Axsome Therapeutics has a consensus price target of $267.60, suggesting a potential upside of 28.79%. Given Indivior's higher possible upside, equities research analysts plainly believe Indivior is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91

In the previous week, Axsome Therapeutics had 9 more articles in the media than Indivior. MarketBeat recorded 13 mentions for Axsome Therapeutics and 4 mentions for Indivior. Indivior's average media sentiment score of 1.04 beat Axsome Therapeutics' score of 0.65 indicating that Indivior is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indivior	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	6 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

60.3% of Indivior shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 0.7% of Indivior shares are held by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Indivior has a beta of 0.82, meaning that its stock price is 18% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.71, meaning that its stock price is 29% less volatile than the broader market.

Indivior has a net margin of 26.65% compared to Axsome Therapeutics' net margin of -24.68%. Axsome Therapeutics' return on equity of -265.55% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	26.65%	-283.11%	36.85%
Axsome Therapeutics	-24.68%	-265.55%	-28.10%

Indivior has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.24B	3.32	$210M	$2.79	12.50
Axsome Therapeutics	$638.50M	17.05	-$183.17M	-$3.75	N/A

Summary

Indivior beats Axsome Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Indivior News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INDV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INDV vs. The Competition

Export

Metric	Indivior	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.21B	$12.48B	$7.26B	$13.14B
Dividend Yield	N/A	2.63%	2.57%	12.30%
P/E Ratio	12.50	797.25	275.79	25.40
Price / Sales	3.32	950.97	695.58	114.44
Price / Cash	13.12	88.44	77.42	51.66
Price / Book	-44.72	10.53	10.46	6.33
Net Income	$210M	$2.82B	$3.49B	$358.33M
7 Day Performance	1.13%	1.69%	0.59%	1.12%
1 Month Performance	-10.66%	0.83%	-2.01%	-2.67%
1 Year Performance	54.95%	3.90%	18.09%	6.01%

Indivior Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INDV Indivior	4.0806 of 5 stars	$34.88 -2.3%	$45.17 +29.5%	+52.4%	$4.21B	$1.24B	12.50	838	News Coverage Positive News Dividend Announcement High Trading Volume
JAZZ Jazz Pharmaceuticals	4.3551 of 5 stars	$244.60 -0.5%	$286.72 +17.2%	+83.5%	$15.86B	$4.60B	16.85	2,890
NBIX Neurocrine Biosciences	4.7846 of 5 stars	$152.94 -2.7%	$201.09 +31.5%	+0.4%	$15.61B	$3.37B	22.51	2,000	Positive News Analyst Upgrade Insider Trade
CORT Corcept Therapeutics	4.1805 of 5 stars	$110.58 -1.1%	$138.17 +24.9%	+38.2%	$11.94B	$761.41M	262.88	730	Trending News Analyst Forecast Insider Trade Analyst Revision
ELAN Elanco Animal Health	4.3184 of 5 stars	$22.95 -0.9%	$29.09 +26.8%	+17.1%	$11.49B	$5.02B	N/A	9,400	Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INDV) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Indivior (INDV) Competitors

INDV vs. JAZZ, NBIX, CORT, ELAN, and AXSM

How does Indivior compare to Jazz Pharmaceuticals?

Summary

How does Indivior compare to Neurocrine Biosciences?

Summary

How does Indivior compare to Corcept Therapeutics?

Summary

How does Indivior compare to Elanco Animal Health?

Summary

How does Indivior compare to Axsome Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDV vs. The Competition

Indivior Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Indivior (INDV) Competitors

INDV vs. JAZZ, NBIX, CORT, ELAN, and AXSM

How does Indivior compare to Jazz Pharmaceuticals?

Do insiders and institutionals hold more shares of INDV or JAZZ?

Is INDV or JAZZ more profitable?

Do analysts prefer INDV or JAZZ?

Which has more risk and volatility, INDV or JAZZ?

Which has higher valuation and earnings, INDV or JAZZ?

Does the media refer more to INDV or JAZZ?

Summary

How does Indivior compare to Neurocrine Biosciences?

Do insiders & institutionals hold more shares of INDV or NBIX?

Which has more risk and volatility, INDV or NBIX?

Is INDV or NBIX more profitable?

Do analysts rate INDV or NBIX?

Does the media refer more to INDV or NBIX?

Which has preferable valuation & earnings, INDV or NBIX?

Summary

How does Indivior compare to Corcept Therapeutics?

Is INDV or CORT more profitable?

Does the media refer more to INDV or CORT?

Which has stronger valuation & earnings, INDV or CORT?

Do institutionals & insiders hold more shares of INDV or CORT?

Which has more volatility and risk, INDV or CORT?

Do analysts prefer INDV or CORT?

Summary

How does Indivior compare to Elanco Animal Health?

Is ELAN or INDV more profitable?

Which has more risk and volatility, ELAN or INDV?

Do institutionals & insiders have more ownership in ELAN or INDV?

Do analysts rate ELAN or INDV?

Which has better earnings and valuation, ELAN or INDV?

Does the media favor ELAN or INDV?

Summary

How does Indivior compare to Axsome Therapeutics?

Do analysts recommend INDV or AXSM?

Does the media refer more to INDV or AXSM?

Do institutionals and insiders hold more shares of INDV or AXSM?

Which has more volatility and risk, INDV or AXSM?

Is INDV or AXSM more profitable?

Which has stronger valuation and earnings, INDV or AXSM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDV vs. The Competition

Indivior Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools